Immutep AIPAC Trial Results: Eftilagimod Alpha with Paclitaxel in HR+ Breast Cancer

Phase IIb trial results from AIPAC study evaluating eftilagimod alpha (soluble LAG-3 protein) combined with weekly paclitaxel versus paclitaxel alone in hormone receptor-positive metastatic breast cancer. While efti did not meet primary PFS endpoint, favorable ORR trends and OS improvements were observed in subgroups, particularly patients under 65 years old, with sustained CD8 T-cell activation and good tolerability.